Chadds Ford-based MOBILion Systems is shaking up the healthcare industry with a biotechnology innovation usually associated with Bay Area startups and high-tech labs in Boston, writes Catherine Odom for the Daily Local news.

The local startup is using Structures for Lossless Ion Manipulation – aka SLIM – technology to “accelerate the analysis of clinically significant molecules to ultimately improve how our customers predict, diagnose, and treat disease,” said CEO Melissa Sherman.

MOBILion’s instruments provide its users with a way to identify molecules that either indicate disease or are significant in drug development that cannot be seen by other similar technologies.

“It’s fast, it’s efficient, and it’s high-powered from a resolution perspective, so we say we reveal what others leave unseen,” said Sherman.

MOBILion aims to commercialize SLIM technology for its customers, including diagnostics and pharmaceutical, to create a product that is manufacturable, scalable, and can be used by mass customers.

The technology is already being used in the development of the COVID-19 vaccine.

“Researchers are learning that the structure and the composition of the glycoproteins on the spikes dictate how the virus works and ultimately dictate and inform vaccine developers and drug developers,” said Sherman.

Read more about MOBILion Systems in the Daily Local News here.

You Might Also Like

Developer Plans to Build World’s Largest Cell, Gene Therapy Manufacturing Facility in KOP

Pharma Firm in New Jersey to Buy Exton-Based Biotechnology Company for $63.3 Million

New Ad Campaign Promotes Chester County, Delaware Valley as ‘Cellicon Valley’